Shanghai, January 8, 2026 —Luye Pharma Group today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the New Drug Appli...
Recently, as a partner of the "Peking University Luye Biomedical Innovation Fund," Luye Life Sciences Group was invited to visit Peking University. The delegation, including Mr. Yang Liang, ...
Shanghai, December 7, 2025 – Luye Pharma Group today announced that five new products have been included in the 2025 edition of the National Reimbursement Drug List for Basic Medical Insurance, ...
Boan Biotech today announced that its aflibercept intravitreous injection Boyoujing® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of neovascular...
Boan Biotech today announced that the preliminary results of the ongoing Phase I clinical study for its BA1301, an investigational antibody-drug conjugate (ADC), were recently presented at the 2025 Co...
- New Product Sales Up 32%, International Strategy Upgraded -Shanghai, August 28, 2025 -- Luye Pharma Group (2186.HK) today announced its 2025 half-year results and latest developments. During the rep...
Boan Biotech (6955.HK) today announced its 2025 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 393 million, up 8% YoY, and the contribut...
Yantai, August 8, 2025 –- Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping®(Dulaglutide Injection), indic...
Shanghai, April 10, 2025 – Luye Pharma Group announced the recent launch of its rotigotine transdermal patch, Rotigotine Luye, in the UK. This product is indicated for the treatment of the signs...
Tokyo, March 31, 2025 – Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Mini...
TOP